MoneyWorks4Me

Mankind Pharma - Quaterly Results

31 Jul 2026 Evaluate
The June 2026 quarter revenue stood at Rs. 29640.50 millions, up 15.34% as compared to Rs. 25697.30 millions during the corresponding quarter last year.A comparatively good net profit growth of 34.49% to Rs. 5584.90 millions was reported for the quarter ended June 2026 compared to Rs. 4152.70 millions of previous same quarter.The company reported a good operating profit of 9625.40 millions compared to 7501.40 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 29640.50 25697.30 15.34 29640.50 25697.30 15.34 104211.80 95074.10 9.61
Other Income 339.60 652.10 -47.92 339.60 652.10 -47.92 3261.00 4934.20 -33.91
PBIDT 9625.40 7501.40 28.31 9625.40 7501.40 28.31 34120.20 29182.40 16.92
Interest 949.50 1493.40 -36.42 949.50 1493.40 -36.42 5622.10 3769.80 49.14
PBDT 8675.90 6008.00 44.41 8675.90 6008.00 44.41 27435.70 25412.60 7.96
Depreciation 1110.20 1046.30 6.11 1110.20 1046.30 6.11 4285.70 3947.60 8.56
PBT 7565.70 4961.70 52.48 7565.70 4961.70 52.48 23150.00 21465.00 7.85
TAX 1980.80 809.00 144.85 1980.80 809.00 144.85 2774.40 4217.40 -34.22
Deferred Tax 327.40 -112.40 -391.28 327.40 -112.40 -391.28 -1957.80 -481.90 306.27
PAT 5584.90 4152.70 34.49 5584.90 4152.70 34.49 20375.60 17247.60 18.14
Equity 413.00 412.70 0.07 413.00 412.70 0.07 412.80 412.60 0.05
PBIDTM(%) 32.47 29.19 11.24 32.47 29.19 11.24 32.74 30.69 6.67

Mankind Pharma Share Price

2424.65 -0.35 (-0.01%)
12-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.00
Dr. Reddys Labs. 1198.95
Cipla 1461.55
Lupin 2264.70
Zydus Lifesciences 1204.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: